Brucellosis Vaccine Market (Type: RB51 Vaccine, S19 Vaccine, and Others; Vaccine Type: DNA Vaccine, Subunit Vaccine, Vector Vaccine, and Recombinant Vaccine; Application: Cattle, Sheep & Goat, and Others; and Distribution Channel: Veterinary Hospitals & Clinics, Retail Channels, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2030

The global Brucellosis Vaccine market gathered revenue around USD 265.1 Million in 2021 and market is set to grow USD 390.4 Million by the end of 2030 and is estimated to expand at a modest CAGR of 4.2% during the prediction period 2022 to 2030.

Growth Factors:

Brucellosis is an extremely transmissible zoonotic infection. Brucella are transferred from animals to humans through the consumption of infected foodstuff, undercooked meat, or unpasteurized milk from diseased animals; direct contact with an infected animal or their discharges, or inhalation of aerosols. Different types of vaccine are available for brucellosis including RB51 vaccine and S19 vaccine. The global brucellosis vaccine market is driven by rise in prevalence of brucellosis and increase in investments by government bodies.

Asia Pacific dominated the global brucellosis vaccine market in 2020, and the trend is anticipated to continue during the forecast period. Increase in livestock population, launch of new products, high prevalence rate of brucellosis, and presence of major players are expected to propel the brucellosis vaccine market in Asia Pacific during the forecast period. Asia Pacific is likely to be a highly lucrative market for brucellosis vaccines during the forecast period. The market in the region is likely to expand at a high CAGR from 2022 to 2030.

Report Scope of the Brucellosis Vaccine Market

Report Coverage

Details

Market Size

US$ 265.1 Million by 2030

Growth Rate

CAGR of 4.2% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year

2021

Forecast Period

2022 to 2030

Segments Covered

Product, Source, Application, End-user and Region,

Companies Mentioned

 STEMCELL Technologies, Inc., Astellas Pharma, Inc., Cellular Engineering Technologies, Inc., BioTime, Inc., Takara Bio, Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics, Inc., Cytori Therapeutics, Inc., Osiris Therapeutics, Inc., and Caladrius Biosciences, Inc.

 Rise in Prevalence of Brucellosis and Increase in Investments by Government Bodies to Drive Global Market

Increase in the number of animals suffering from brucellosis is projected to boost the growth of the global brucellosis vaccine market from 2021 to 2031. Globalization and climate change lead to outbreak of animal diseases; some of these are transmissible to humans. According to the IFAH Europe, rise in global temperatures leads to appearance of new diseases and helps other diseases to reappear. Most human zoonotic infections are transmitted by livestock. Zoonotic diseases account for 61% of the total animal diseases. Increase in livestock population in countries such as India and China is anticipated to drive the demand for brucellosis vaccines in the near future.

Government initiatives play an important role in the growth of the animal healthcare segment. For instance, compulsory immunization policy in China, availability of affordable veterinary vaccines, awareness programs & funding for research & development are expected to drive the global veterinary healthcare market. The Animal and Plant Health Agency (APHA) received US$ 100,000 in the AgResults’ Brucellosis Vaccine Prize competition, aimed at incentivizing the development of a vaccine that is effective, safe, and viable for use against brucella melitensis in small ruminants across the developing world.

RB51 Vaccine to Dominate Brucellosis Vaccine Market

In terms of type, the global brucellosis vaccine market has been classified into RB51 vaccine, S19 vaccine, and others. The RB51 vaccine segment dominated the global brucellosis vaccine market in 2020, and the trend is expected to continue during the forecast period. RB51 vaccine is the most common vaccine used for brucellosis. Vaccination of pregnant cows with strain RB51 can induce low levels of abortion (less than 0.2%); however, it is safe at lower doses during pregnancy. This is likely to propel the segment during the forecast period. Additionally, increase in preference for RB51 vaccine over others due to high efficiency in low dose is projected to augment the segment in the next few years.

DNA Vaccine Held Significant Market Share in 2020

Based on vaccine type, the global brucellosis vaccine market has been categorized into DNA vaccine, subunit vaccine, vector vaccine, and recombinant vaccine. The DNA vaccine segment led the global brucellosis vaccine market in terms of revenue in 2020 and the trend is anticipated to continue during the forecast period. DNA vaccination provided a new and valuable approach to the development of brucellosis vaccines and offered advantages in flexibility of design, speed, simplicity of production, and the ability to elicit both cellular and humoral immune responses. This factor is expected to fuel the growth of the segment during the forecast period.

Cattle to be Highly Lucrative Application

In terms of application, the global brucellosis vaccine market has been segregated into cattle, sheep & goat, and others. The segment is likely to account for significant market share during the forecast period due to the high usage of these vaccines for cattle. Additionally, increase in cattle population in countries such as India and Brazil is projected to propel the segment over the next few years. According to study, Brazil had around 145 million cattle in 2020.

Veterinary Hospitals & Clinics to be Major Distribution Channel

Based on distribution channel, the global brucellosis vaccine market has been divided into veterinary hospitals & clinics, retail channels, and others. The veterinary hospitals & clinics segment led the global brucellosis vaccine market in terms of revenue in 2020. The trend is projected to continue during the forecast period due to increase in inclination of owners to avail various vaccines that veterinary clinics offer and rise in preference for veterinary hospitals & clinics for vaccination.

Asia Pacific to Dominate Brucellosis Vaccine Market

In terms of region, the global brucellosis vaccine market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific dominated the global brucellosis vaccine market in 2020, followed by Europe. Asia Pacific's large market share can be ascribed to increase in livestock population, rise in number of brucellosis cases, less awareness about diseases, new product launches, and presence of major players.

The brucellosis vaccine market in Asia Pacific is anticipated to expand at a high CAGR from 2022 to 2030. This can be ascribed to the presence of developing countries with commercial hubs, expanding business organizations, improving health care infrastructure, and increase in investments by companies.

Some of the prominent players in the Brucellosis Vaccine Market include:  Merck Animal Health, Ceva Sante Animale, CZ Vaccines, Colorado Serum Company, Indian Immunologicals Ltd., Hester Biosciences Limited, Veterinary Technologies Corporation, Fivet Animal Health, Jordan Bio-industries Center, and Laboratories Tornel.

Segments Covered in the Report

This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for the period of 2017 to 2030 and covers subsequent region in its scope:

  • Brucellosis Vaccine Market, by Type
    • RB51 Vaccine
    • S19 Vaccine
    • Others
  • Brucellosis Vaccine Market, by Vaccine Type
    • DNA Vaccine
    • Subunit Vaccine
    • Vector Vaccine
    • Recombinant Vaccine
  • Brucellosis Vaccine Market, by Application
    • Cattle
    • Sheep & Goat
    • Others
  • Brucellosis Vaccine Market, by Distribution Channel
    • Veterinary Hospitals & Clinics
    • Retail Channels
    • Others

By Geography

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • United Kingdom
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Rest of Latin America

Middle East & Africa (MEA)

  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East & Africa

Key Points Covered in Brucellosis Vaccine Market Study:

  • Growth of Brucellosis Vaccine in 2022
  • Market Estimates and Forecasts (2017-2030)
  •  Brand Share and Market Share Analysis
  •  Key Drivers and Restraints Shaping Market Growth
  •  Segment-wise, Country-wise, and Region-wise Analysis
  •  Competition Mapping and Benchmarking
  •  Recommendation on Key Winning Strategies
  •  COVID-19 Impact on Demand for Brucellosis Vaccine and How to Navigate
  •  Key Product Innovations and Regulatory Climate
  •  Brucellosis Vaccine Consumption Analysis
  •  Brucellosis Vaccine Production Analysis
  •  Brucellosis Vaccine and Management

1. Preface

    1.1. Report Scope and Market Segmentation

    1.2. Research Highlights

2. Assumptions and Research Methodology

    2.1. Assumptions and Acronyms Used

    2.2. Research Methodology

3. Executive Summary

4. Market Overview

    4.1. Introduction

    4.2. Market Dynamics

        4.2.1. Drivers

        4.2.2. Restraints

        4.2.3. Opportunity

    4.3. Global Brucellosis Vaccine Market Forecast

    4.4. Global Brucellosis Vaccine Market Outlook

5. Market Outlook

    5.1. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)

    5.2. Disease Prevalence globally with key countries

    5.3. Regulatory Scenario

    5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

6. Global Brucellosis Vaccine Market Analysis and Forecast, by Type

    6.1. Introduction

    6.2. Global Brucellosis Vaccine Market Value Share Analysis, by Type

    6.3. Global Brucellosis Vaccine Market Forecast, by Type

        6.3.1. RB51 Vaccine

        6.3.2. S19 Vaccine

        6.3.3. Others

    6.4. Global Brucellosis Vaccine Market Analysis, by Type

    6.5. Global Brucellosis Vaccine Market Attractiveness Analysis, by Type

7. Global Brucellosis Vaccine Market Analysis and Forecast, by Vaccine Type

    7.1. Introduction

    7.2. Global Brucellosis Vaccine Market Value Share Analysis, by Vaccine Type

    7.3. Global Brucellosis Vaccine Market Forecast, by Vaccine Type

        7.3.1. DNA Vaccine

        7.3.2. Subunit Vaccine

        7.3.3. Vector Vaccine

    7.4. Recombinant Vaccine

    7.5. Global Brucellosis Vaccine Market Analysis, by Vaccine Type

    7.6. Global Brucellosis Vaccine Market Attractiveness Analysis, by Vaccine Type

8. Global Brucellosis Vaccine Market Analysis and Forecast, by Application

    8.1. Introduction

    8.2. Global Brucellosis Vaccine Market Value Share Analysis, by Application

    8.3. Global Brucellosis Vaccine Market Forecast, by Application

        8.3.1. Cattle

        8.3.2. Sheep & Goat

        8.3.3. Others

    8.4. Global Brucellosis Vaccine Market Analysis, by Application

    8.5. Global Brucellosis Vaccine Market Attractiveness Analysis, by Application

9. Global Brucellosis Vaccine Market Analysis and Forecast, by Distribution Channel

    9.1. Introduction

    9.2. Global Brucellosis Vaccine Market Value Share Analysis, by Distribution Channel

    9.3. Global Brucellosis Vaccine Market Forecast, by Distribution Channel

        9.3.1. Veterinary Hospitals & Clinics

        9.3.2. Retail Channels

        9.3.3. Others

    9.4. Global Brucellosis Vaccine Market Analysis, by Distribution Channel

    9.5. Global Brucellosis Vaccine Market Attractiveness Analysis, by Distribution Channel

10. Global Brucellosis Vaccine Market Analysis, by Region

    10.1. Global Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Region

    10.2. Global Brucellosis Vaccine Market Forecast, by Region

        10.2.1. North America

        10.2.2. Europe

        10.2.3. Asia Pacific

        10.2.4. Latin America

        10.2.5. Middle East & Africa

11. North America Brucellosis Vaccine Market Analysis

    11.1. North America Brucellosis Vaccine Market Overview

    11.2. North America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Country

    11.3. North America Brucellosis Vaccine Market Forecast, by Country

        11.3.1. U.S.

        11.3.2. Canada

    11.4. North America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Type

    11.5. North America Brucellosis Vaccine Market Forecast, by Type

        11.5.1. RB51 Vaccine

        11.5.2. S19 Vaccine

        11.5.3. Others

    11.6. North America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Vaccine Type

    11.7. North America Brucellosis Vaccine Market Forecast, by Vaccine Type

        11.7.1. DNA Vaccine

        11.7.2. Subunit Vaccine

        11.7.3. Vector Vaccine

        11.7.4. Recombinant Vaccine

    11.8. North America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Application

    11.9. North America Brucellosis Vaccine Market Forecast, by Application

        11.9.1. Cattle

        11.9.2. Sheep & Goat

        11.9.3. Others

    11.10. North America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Distribution Channel

    11.11. North America Brucellosis Vaccine Market Forecast, by Distribution Channel

        11.11.1. Veterinary Hospitals & Clinics

        11.11.2. Retail Channels

        11.11.3. Others

12. Europe Brucellosis Vaccine Market Analysis

    12.1. Europe Brucellosis Vaccine Market Overview

    12.2. Europe Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Country/Sub-region

    12.3. Europe Brucellosis Vaccine Market Forecast, by Country/Sub-region

        12.3.1. Germany

        12.3.2. U.K.

        12.3.3. France

        12.3.4. Spain

        12.3.5. Italy

        12.3.6. Rest of Europe

    12.4. Europe Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Type

    12.5. Europe Brucellosis Vaccine Market Forecast, by Type

        12.5.1. RB51 Vaccine

        12.5.2. S19 Vaccine

        12.5.3. Others

    12.6. Europe Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Vaccine Type

    12.7. Europe Brucellosis Vaccine Market Forecast, by Vaccine Type

        12.7.1. DNA Vaccine

        12.7.2. Subunit Vaccine

        12.7.3. Vector Vaccine

        12.7.4. Recombinant Vaccine

    12.8. Europe Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Application

    12.9. Europe Brucellosis Vaccine Market Forecast, by Application

        12.9.1. Cattle

        12.9.2. Sheep & Goat

        12.9.3. Others

    12.10. Europe Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Distribution Channel

    12.11. Europe Brucellosis Vaccine Market Forecast, by Distribution Channel

        12.11.1. Veterinary Hospitals & Clinics

        12.11.2. Retail Channels

        12.11.3. Others

13. Asia Pacific Brucellosis Vaccine Market Analysis

    13.1. Asia Pacific Brucellosis Vaccine Market Overview

    13.2. Asia Pacific Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Country/Sub-region

    13.3. Asia Pacific Brucellosis Vaccine Market Forecast, by Country/Sub-region

        13.3.1. China

        13.3.2. Japan

        13.3.3. India

        13.3.4. Australia & New Zealand

        13.3.5. Rest of Asia Pacific

    13.4. Asia Pacific Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Type

    13.5. Asia Pacific Brucellosis Vaccine Market Forecast, by Type

        13.5.1. RB51 Vaccine

        13.5.2. S19 Vaccine

        13.5.3. Others

    13.6. Asia Pacific Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Vaccine Type

    13.7. Asia Pacific Brucellosis Vaccine Market Forecast, by Vaccine Type

        13.7.1. DNA Vaccine

        13.7.2. Subunit Vaccine

        13.7.3. Vector Vaccine

        13.7.4. Recombinant Vaccine

    13.8. Asia Pacific Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Application

    13.9. Asia Pacific Brucellosis Vaccine Market Forecast, by Application

        13.9.1. Cattle

        13.9.2. Sheep & Goat

        13.9.3. Others

    13.10. Asia Pacific Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Distribution Channel

    13.11. Asia Pacific Brucellosis Vaccine Market Forecast, by Distribution Channel

        13.11.1. Veterinary Hospitals & Clinics

        13.11.2. Retail Channels

        13.11.3. Others

14. Latin America Brucellosis Vaccine Market Analysis

    14.1. Latin America Brucellosis Vaccine Market Overview

    14.2. Latin America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Country/Sub-region

    14.3. Latin America Brucellosis Vaccine Market Forecast, by Country/Sub-region

        14.3.1. Brazil

        14.3.2. Mexico

        14.3.3. Rest of Latin America

    14.4. Latin America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Type

    14.5. Latin America Brucellosis Vaccine Market Forecast, by Type

        14.5.1. RB51 Vaccine

        14.5.2. S19 Vaccine

        14.5.3. Others

    14.6. Latin America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Vaccine Type

    14.7. Latin America Brucellosis Vaccine Market Forecast, by Vaccine Type

        14.7.1. DNA Vaccine

        14.7.2. Subunit Vaccine

        14.7.3. Vector Vaccine

        14.7.4. Recombinant Vaccine

    14.8. Latin America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Application

    14.9. Latin America Brucellosis Vaccine Market Forecast, by Application

        14.9.1. Cattle

        14.9.2. Sheep & Goat

        14.9.3. Others

    14.10. Latin America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Distribution Channel

    14.11. Latin America Brucellosis Vaccine Market Forecast, by Distribution Channel

        14.11.1. Veterinary Hospitals & Clinics

        14.11.2. Retail Channels

        14.11.3. Others

15. Middle East & Africa Brucellosis Vaccine Market Analysis

    15.1. Middle East & Africa Brucellosis Vaccine Market Overview

    15.2. Middle East & Africa Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Country/Sub-region

    15.3. Middle East & Africa Brucellosis Vaccine Market Forecast, by Country/Sub-region

        15.3.1. GCC Countries

        15.3.2. South Africa

        15.3.3. Rest of Middle East & Africa

    15.4. Middle East & Africa Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Type

    15.5. Middle East & Africa Brucellosis Vaccine Market Forecast, by Type

        15.5.1. RB51 Vaccine

        15.5.2. S19 Vaccine

        15.5.3. Others

    15.6. Middle East & Africa Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Vaccine Type

    15.7. Middle East & Africa Brucellosis Vaccine Market Forecast, by Vaccine Type

        15.7.1. DNA Vaccine

        15.7.2. Subunit Vaccine

        15.7.3. Vector Vaccine

        15.7.4. Recombinant Vaccine

    15.8. Middle East & Africa Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Application

    15.9. Middle East & Africa Brucellosis Vaccine Market Forecast, by Application

        15.9.1. Cattle

        15.9.2. Sheep & Goat

        15.9.3. Others

    15.10. Middle East & Africa Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Distribution Channel

    15.11. Middle East & Africa Brucellosis Vaccine Market Forecast, by Distribution Channel

        15.11.1. Veterinary Hospitals & Clinics

        15.11.2. Retail Channels

        15.11.3. Others

16. Competition Landscape

    16.1. Company Profiles

        16.1.1. Merck Animal Health

            16.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.1.1.2. Product Portfolio

            16.1.1.3. Financial Overview

            16.1.1.4. SWOT Analysis

            16.1.1.5. Strategic Overview

        16.1.2. Ceva Sante Animale

            16.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.1.2.2. Product Portfolio

            16.1.2.3. SWOT Analysis

            16.1.2.4. Strategic Overview

        16.1.3. CZ Vaccines

            16.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.1.3.2. Product Portfolio

            16.1.3.3. SWOT Analysis

            16.1.3.4. Strategic Overview

        16.1.4. Colorado Serum Company

            16.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.1.4.2. Product Portfolio

            16.1.4.3. SWOT Analysis

            16.1.4.4. Strategic Overview

        16.1.5. Indian Immunologicals Ltd.

            16.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.1.5.2. Product Portfolio

            16.1.5.3. SWOT Analysis

            16.1.5.4. Strategic Overview

        16.1.6. Hester Biosciences Limited

            16.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.1.6.2. Product Portfolio

            16.1.6.3. Financial Overview

            16.1.6.4. SWOT Analysis

            16.1.6.5. Strategic Overview

        16.1.7. Veterinary Technologies Corporation.

            16.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.1.7.2. Product Portfolio

            16.1.7.3. SWOT Analysis

            16.1.7.4. Strategic Overview

        16.1.8. Fivet Animal Health

            16.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.1.8.2. Product Portfolio

            16.1.8.3. SWOT Analysis

            16.1.8.4. Strategic Overview

        16.1.9. Jordan Bio-industries Center

            16.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.1.9.2. Product Portfolio

            16.1.9.3. SWOT Analysis

            16.1.9.4. Strategic Overview

        16.1.10. Laboratories Tornel

            16.1.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.1.10.2. Product Portfolio

            16.1.10.3. SWOT Analysis

            16.1.10.4. Strategic Overview

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask To Expert